USANA Health Sciences, Inc. — Form 10-Q Summary
Period discrepancy: The request metadata identifies 2015 Q1, but the filing is for the quarter ended April 2, 2016, compared with the quarter ended April 4, 2015. The summary below follows the filing.
Business context and reporting period
USANA develops and manufactures nutrition and personal-care products sold internationally through a direct-selling network. It reported approximately 437,000 active Associates and 94,000 active Preferred Customers. Asia Pacific generated 73.4% of quarterly sales; sales outside the United States were 85.5% of consolidated sales.
Financial performance
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Net sales | $240.4 million | $219.4 million | +9.6% |
| Gross profit / margin | $197.5 million / 82.2% | $181.0 million / 82.5% | Margin down 0.3 percentage points |
| Operating earnings | $33.5 million | $29.8 million | +12.5% |
| Net earnings | $22.3 million | $19.7 million | +13.3% |
| Diluted EPS | $1.77 | $1.50 | +18.0% |
| Operating cash flow | $13.5 million | $23.6 million | Down $10.1 million |
Gross margin was pressured by currency movements, partly offset by product and market mix and modest price adjustments. Associate incentives declined to 44.7% of sales from 46.2%, while SG&A rose to 23.6% from 22.7%, reflecting strategic investments and higher equity compensation. The effective tax rate fell to 32.4% from 34.3%, including a benefit from adopting a share-based compensation accounting standard and a federal research credit.
Balance sheet, liquidity, and capital allocation
- At April 2, 2016, cash and equivalents were $150.5 million, current assets $243.4 million, and current liabilities $112.8 million; reported net working capital was $130.7 million.
- Long-term line-of-credit debt was $66.0 million, versus no balance at January 2, 2016. Cash exceeded this debt by $84.5 million. The company said it intended to repay the outstanding balance within the next 12 months.
- Operating cash flow was lower year over year, primarily reflecting changes in liabilities and related working-capital movements. Capital spending was $9.0 million; cash increased $7.3 million during the quarter.
- USANA repurchased 553,082 shares for $64.6 million, averaging $116.82 per share. $35.4 million remained authorized for repurchases, with no obligation to use it.
- The amended credit facility runs to April 2021, with borrowing capacity up to $125 million through October 31, 2016, then reverting to $75 million. The company reported compliance with its covenants, including minimum adjusted EBITDA of $100 million and a funded-debt-to-adjusted-EBITDA limit of 2.0:1.
Material changes and management commentary
- Sales growth reflected higher product volume and customer growth; unfavorable exchange rates reduced reported sales by approximately $14.2 million. Sales grew 16.1% excluding currency impact.
- Greater China sales rose 15.5% reported and 20.8% excluding currency impact. The United States declined 4.0%, which management attributed to fewer active customers.
- Active Associates increased 16.2% year over year and Preferred Customers increased 9.3%. China was the largest market, with $100.5 million in sales.
- Management expected its China manufacturing facility to become operational in the first half of 2016. The anticipated project investment was $40 million; $29.1 million had been incurred through quarter-end.
- Management stated that cash, operating cash flow, and available credit should cover ordinary operating and capital needs, while cautioning that adverse conditions or unexpected capital needs could require additional financing. No specific earnings or revenue guidance was provided.
Risks, contingencies, and unusual items
- Foreign-exchange exposure is significant; the company uses short-term currency contracts, not designated as accounting hedges. The quarter included a $1.3 million net loss on these contracts.
- There are ongoing ordinary-course legal matters. No contingency liability was accrued because management considered none probable and estimable. A shareholder derivative suit concerning 2014 equity awards was on appeal; management considered the claims without merit and did not expect a material adverse effect.
- $142.0 million of the $150.5 million cash balance was held by international subsidiaries. Repatriation of $18.2 million of indefinitely reinvested earnings was estimated to incur approximately $3.1 million in tax.
- Key stated risks include reliance on independent Associates and network marketing, China expansion, regulation, competition, suppliers and product liability, currency volatility, and compliance with debt covenants.
- The company early adopted accounting updates affecting share-based compensation and deferred-tax presentation. Management reported effective disclosure controls and no material quarter-over-quarter change in internal control over financial reporting.
Most important facts to verify
- Confirm the reporting-period mismatch: the filing covers Q1 2016, not Q1 2015.
- Assess whether customer growth, particularly in China, can continue and whether U.S. customer declines persist.
- Track foreign-exchange effects on reported sales, margins, and derivative results.
- Verify repayment of the $66.0 million credit balance and continued compliance with the tighter credit covenants.
- Monitor cash conversion, planned China-facility spending and launch timing, and the outcome of the shareholder litigation.